Evinacumab to treat hypercholesterolemia.

Area of Science:

• Cardiology
• Biochemistry
• Pharmacology

Background:

• Cardiovascular disease (CVD) is a leading global cause of death, primarily driven by atherosclerosis.
• Elevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerosis.
• Existing therapies and lifestyle changes are insufficient for some patients, particularly those with genetic dyslipidemias like familial hypercholesterolemia, leading to persistent high cardiovascular risk.

Purpose of the Study:

• To evaluate the efficacy of evinacumab, a novel human monoclonal antibody, in managing dyslipidemia.
• To assess the impact of ANGPTL3 inhibition on lipid profiles in patients with genetically induced dyslipidemias.
• To determine if evinacumab can help patients reach their lipid targets and reduce cardiovascular risk.

Main Methods:

• Evinacumab, a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), was administered to patients.
• The study assessed the drug's mechanism, involving increased lipoprotein lipase (LPL) and endothelial lipase (EL) activity.
• Changes in circulating lipid levels, including very-low-density lipoprotein cholesterol (VLDL-C), triglycerides, LDL-C, and high-density lipoprotein cholesterol (HDL-C), were measured.

Main Results:

• Evinacumab significantly reduced circulating levels of VLDL-C, triglycerides, LDL-C, and HDL-C.
• The drug demonstrated increased activity of LPL and EL, key enzymes in lipid metabolism.
• A significant decrease in overall lipids and achievement of lipid targets were observed in treated patients.

Conclusions:

• Evinacumab is effective in significantly decreasing circulating lipids.
• The ANGPTL3 inhibitor facilitates the attainment of lipid targets in patients with challenging dyslipidemias.
• Further research is warranted to confirm evinacumab's long-term impact on cardiovascular risk and mortality.